Health Care

The GOP Has One Last Health Care Plan. It Would Also Cause Millions to Lose Coverage

By Michael Rainey

Now that Republicans have failed to pass multiple versions of health care bills to repeal and replace Obamacare, or just repeal it, there’s only one GOP health care bill left floating around: one...
A Growing List of Bipartisan Ideas for Fixing Obamacare

By Michael Rainey

The failure of the most recent Republican attempt to repeal and replace the Affordable Care means that Obamacare will likely be with us for the foreseeable future. This political reality has given a...
What Can Be Done About Rising Drug Prices?

By Yuval Rosenberg

Republican efforts to repeal and replace Obamacare may have collapsed, but as Northern Trust economists Carl R. Tannenbaum and Ankit Mital wrote in a note published Friday , there’s a broader...
Why Republicans Can’t Cure Their Obamacare Hangover

By Edward Morrissey

With repeal and replace dead at the moment, Republicans in Congress and in the White House now have to make a choice in how to deal with Obamacare. Do they attempt to manage it as best as possible,...
Obamacare Premiums and Budget Deficits Will Soar If Trump Ends Insurer Subsidies

By Rob Garver

If the Trump administration follows through on its threat to stop paying insurance companies a controversial set of subsidies established by the Affordable Care Act, the government will lose money...

One More Try? Why Obamacare Repeal Is on the Horizon Again

By Rob Garver

The effort to repeal and replace the Affordable Care Act, which many assumed was dead or at least in a state of suspended animation for the foreseeable future, may be showing some stirring of life...
Taxpayers Will Pay the Price for Uncertainty Over Obamacare in 2018

By Rob Garver

On average, the amount of premium payment picked up by the federal government will increase by about 63 percent in the states reviewed by the Kaiser Family Foundation.
Here’s Medicare for All: Long Wait Times, Fewer Doctors, and Huge Tax Hikes

By Edward Morrissey

Fresh off his surprisingly close challenge of Hillary Clinton in the 2016 primaries – and her ignominious defeat in the general election – Bernie Sanders has emerged as the leader of progressive...
Heads Up: Health Care Is Still in Trouble

By Rob Garver

The issue of the US health insurance system was taken off the front burner with the evident failure of the Republican effort to repeal and replace the Affordable Care Act. But while it may not be in...
Here’s How Much More Your Health Insurance Will Cost Next Year

By Beth Braverman

Consumers who get health insurance through their jobs won’t see rate hikes in the double digits like those on the Obamacare exchanges, but they’ll still see the cost of health care go up.

Exclusive: Warburg tops $5 billion mark for fund: sources

By Greg Roumeliotis and Paritosh Bansal, Reuters

NEW YORK (Reuters) - Warburg Pincus LLC has raised more than $5 billion in just over seven months for its 11th global private equity fund, a major step on the way toward its $12 billion target,...
Insight: Afghan women fade from White House focus as exit nears

By Laura MacInnis and Amie Ferris-Rotman, Reuters

WASHINGTON/KABUL (Reuters) - Shortly after sending U.S. troops to Afghanistan in October 2001, President George W. Bush focused so intently on freeing Afghan women from the shackles of Taliban rule...
Same-sex civil unions bill fails in Colorado

By Keith Coffman, Reuters

DENVER (Reuters) - A Colorado bill that would have allowed same-sex civil unions failed to advance to a full vote on the last day of the legislative session on Wednesday, setting up a potential stand...
Probe finds collusion between India's drug regulator, pharma firms

By Ross Colvin and Kaustubh Kulkarni, Reuters

NEW DELHI/MUMBAI (Reuters) - Officials of India's drug regulator have been colluding with pharmaceutical firms to speed up approval procedures, allowing some drugs that are not permitted in other...
GSK goes hostile with $2.6 billion Human Genome offer

By Ben Hirschler, Reuters

LONDON (Reuters) - GlaxoSmithKline will take its $2.6 billion bid for long-time partner Human Genome Sciences direct to shareholders this week, after its takeover offer was rejected last month by the...

Search form